Lipocine (NASDAQ:LPCN) Now Covered by Analysts at StockNews.com

StockNews.com began coverage on shares of Lipocine (NASDAQ:LPCN) in a report released on Thursday. The brokerage issued a hold rating on the specialty pharmaceutical company’s stock.

Lipocine Trading Up 1.8 %

Shares of NASDAQ:LPCN opened at $3.44 on Thursday. Lipocine has a 1-year low of $2.91 and a 1-year high of $11.79. The firm has a market capitalization of $18.40 million, a PE ratio of -4.53 and a beta of 1.23. The business’s 50 day moving average is $4.13 and its 200-day moving average is $4.54.

Hedge Funds Weigh In On Lipocine

A hedge fund recently raised its stake in Lipocine stock. Geode Capital Management LLC increased its stake in shares of Lipocine Inc. (NASDAQ:LPCN) by 6.0% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 57,464 shares of the specialty pharmaceutical company’s stock after buying an additional 3,248 shares during the quarter. Geode Capital Management LLC owned 1.07% of Lipocine worth $280,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 9.11% of the company’s stock.

About Lipocine

Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.